025 біостартапи

The chart shows the growth of an initial investment of $10,000 in 025 біостартапи, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Mar 23, 2021, 025 біостартапи's average daily return is +0.25%, while the average monthly return is +5.70%. At this rate, your investment would double in approximately 1.0 years.

Historically, 50% of months were positive and 50% were negative. The best month was Oct 2024 with a return of +337.3%, while the worst month was Jan 2022 at -20.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.

On a daily basis, 025 біостартапи closed higher 50% of trading days. The best single day was Oct 15, 2024 with a return of +246.0%, while the worst single day was Oct 16, 2024 at -18.8%.

Portfolio has an annualized alpha of 64.74%, beta of 1.23, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since March 23, 2021.

• This portfolio captured 127.45% of S&P 500 Index gains but only 57.51% of its losses — a favorable profile for investors.
• R² of 0.03 means this portfolio moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

025 біостартапи has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

025 біостартапи ranks 97 for risk / return — in the top 97% of portfolios on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

025 біостартапи Sharpe ratios as of Apr 3, 2026 (values are recalculated daily):

• 1-Year: 3.20
• 5-Year: 0.23
• All Time: 0.22

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 0.98 to 1.66, this portfolio's current Sharpe ratio is in the top 25%. This signifies superior risk-adjusted performance, meaning the portfolio is delivering strong returns for the level of risk taken compared to most others.

The chart below shows the rolling Sharpe ratio of 025 біостартапи compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the 025 біостартапи. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 025 біостартапи was 76.50%, occurring on Oct 27, 2023. Recovery took 242 trading sessions.

The current 025 біостартапи drawdown is 12.17%.

The chart below shows the rolling one-month volatility.